#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“What this research tells us clinically is that we can now counsel patients more precisely about cannabis timing and safety, particularly those concerned about impairment affecting their daytime function or work performance, which has been a legitimate barrier to treatment adherence for many people I see.”
💊 While this article highlights a study suggesting no next-day cognitive impairment from cannabis use, clinicians should interpret this finding with appropriate caution given the limited information available and the heterogeneity of cannabis products, dosing regimens, and individual user factors that influence pharmacokinetics and sensitivity. The evidence base for cannabis effects on next-day functioning remains relatively sparse compared to well-established substances like alcohol, and individual variation in cannabinoid metabolism, frequency of use, and baseline cognitive status may substantially modify risk profiles across different patients. Important confounders such as sleep quality, concurrent medications, underlying sleep disorders, and the specific cannabinoid profile and potency of products used were likely not uniformly controlled across users. In clinical encounters, practitioners should continue to counsel patients that cannabis impairment timing and duration are incompletely characterized, recommend avoiding safety-sensitive activities until individual response is better understood, and assess each patient’s unique risk factors rather than
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: